Akari Therapeutics Plc Appoints Abizer Gaslightwala As President and CEO
03/20/25, 1:18 PM
Location
londonIndustry
biotechnology
Position
chief executive officer
president
Akari Therapeutics Plc announced the appointment of Abizer Gaslightwala as President and Chief Executive Officer (CEO), effective April 21, 2025. He brings 25 years of experience in the biotechnology and pharmaceutical industry, having most recently served as the Senior Vice President and Franchise Head for US Oncology at Jazz Pharmaceuticals.
Company Info
Location
75/76 wimpole street
london, england, united kingdom
Additional Info
Akari Therapeutics, Plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune, oncology and inflammatory diseases. Akari has two lead assets, investigational nomacopan and an antibody drug conjugate (ADC) platform. Nomacopan is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The Company is conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). The Company’s ADC platform includes novel toxins and linkers coupled with important cancer antibody targets.
Related People
Unlock Verified Contacts + AI Outreach
Instantly access verified contact emails — and let Fundz AI draft a hyper-personalized message based on their role, company, and your company's offering.
Th
Th • Executive
Email hidden • Upgrade to unlock
Trusted by teams at Google, Oracle, HubSpot & more
Unlock Verified Contacts + AI Outreach
Instantly access verified contact emails — and let Fundz AI draft a hyper-personalized message based on their role, company, and your company's offering.
Ah
Ah • Executive
Email hidden • Upgrade to unlock
Trusted by teams at Google, Oracle, HubSpot & more